Replies to post #77587 on Avid Bioservices Inc (CDMO)

[freethemice]

Entdoc, I have been thinking about this and I still think it might be true, but for a different reason than before.
See my post # 77572.
Now I think it is because of the properties of docetaxel, which was used in the second-line advanced
breast cancer single-arm trial, and in the current two-arm second-line NSCLC trial. Docetaxel has the ability
to suppress MDSCs, which results in the reduction of immunosuppression. Since one of the MOAs of
bavituximab also does this there may be a synergy which results in a better outcome.
This is also why I think the HCC and pancreatic trials may have good results. Again see my post # 77572.